prospec
CoV-2 N (329 a.a.)

CoV-2 N (329 a.a.)

  • Name
  • Description
  • Cat#
  • Pricings
  • Quantity
  • CoV-2 N (329 a.a.)

  • Coronavirus 2019 Nucleocapsid (329 a.a.), Recombinant
  • SARS-044
  • Shipped with Ice Packs

Catalogue number

SARS-044

Introduction

A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019.

The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2)  in humans.

While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.

Description

The E.Coli derived recombinant protein contains the Coronavirus 2019 C-terminal region 329 a.a. from the Nucleocapsid protein and fused to GST-6xHis tag at N-terminal and having a Mw. of 63.5 kDa.

Source

E.Coli.

Purification Method

NTA Sepharose-Affinity Purification.

Physical Appearance

Sterile Filtered clear solution.

Formulation

CoV-2 Nucleocapsid protein solution is supplied in 50mM Tris-HCl pH 8, 1M Urea, and 50% Glycerol.

Stability

CoV-2 Spike Protein is shipped on ice packs. Upon arrival, Store at -20°C.

Purity

CoV-2 Nucleocapsid protein is >95% pure as determined SDS-PAGE.

Safety Data Sheet

Usage

ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Back to Top